The Nevada Department of Health and Human Services paused the use of Johnson & Johnson COVID-19 vaccine on Tuesday after reports of potentially dangerous blood clots in order to protect “the health and safety of all Nevadans.”
Nevada was among a cascade of states announcing Tuesday they would heed a federal recommendation and halt any administering of the one-shot J&J vaccine.
The pause comes after a joint statement Tuesday from the Centers for Disease Control and Prevention and the Food and Drug Administration announcing investigation of reduced platelet counts and blood clots in six women in the days after vaccination. More than 6.8 million doses of the J&J vaccine had been administered in the U.S as of Monday.
Federal health officials are recommending that people who were given the J&J vaccine – also referred to as Janssen – who are experiencing severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after receiving the shot contact their health care provider.
The State of Nevada will pause the use of the one-shot vaccine until the review is complete. Health officials are contacting providers and working to avoid any disruption of planned vaccination clinics.
Janssen vaccines have been used on the two Mobile Vaccine Units (MVUs) that are traveling in Nevada’s rural and frontier regions, however, no mobile clinics were planned for Tuesday.
In Southern Nevada, about 30,980 Johnson & Johnson vaccine doses have been administrated as of April 7, according to the Southern Nevada Health District. That’s about 3 percent of the total 1 million COVID vaccine shots so far in Southern Nevada.
Pfizer and Moderna vaccines will remain available for providers in Nevada and appointment slots are open across the State.
“Nevadans should be confident in this process and the work being done to ensure the vaccines are safe and effective. Based on information provided by the federal government, these are rare but serious reactions and will be thoroughly reviewed,” said the Nevada Health Response in a statement.
Until the investigation process is complete, “we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in their joint statement.